Community-acquired pneumonia remains the leading cause of hospitalisation for infectious disease in Europe, and a major cause of morbidity and mortality. This issue of the European Respiratory Monograph brings together leading experts in pulmonology, infectious diseases and critical care from around the world to present the most recent advances in the management of community-acquired pneumonia. It provides a comprehensive overview of the disease, including chapters on microbiology, pathophysiology, antibiotic therapy and prevention, along with hot topics such as viral pneumonias and pneumonia associated with inhaled corticosteroids.Therefore, paediatricians tend to use antibiotics to treat almost all cases of CAP, including those that are more likely due to viruses but ... fees for satellite symposia from AstraZeneca, Crucell and GSK, and for work on the Board from V- Pharma, all outside the work of the current manuscript. ... Antibiotic therapy for pediatric community-acquired pneumonia: do we know when, what and for how long to treat?
|Title||:||European Respiratory Monograph 63: Community-Acquired Pneumonia|
|Author||:||James Chalmers, Mathias Pletz, Stefano Aliberti|
|Publisher||:||European Respiratory Society - 2014-03-01|